TY - JOUR
T1 - Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
AU - Seow, Jeffrey
AU - Graham, Carl
AU - Merrick, Blair
AU - Acors, Sam
AU - Pickering, Suzanne
AU - Steel, Kathryn J. A.
AU - Hemmings, Oliver
AU - O’Byrne, Aoife
AU - Kouphou, Neophytos
AU - Galao, Rui Pedro
AU - Betancor, Gilberto
AU - Wilson, Harry D.
AU - Signell, Adrian W.
AU - Winstone, Helena
AU - Kerridge, Claire
AU - Huettner, Isabella
AU - Jimenez-Guardeño, Jose M.
AU - Lista, Maria Jose
AU - Temperton, Nigel
AU - Snell, Luke B.
AU - Bisnauthsing, Karen
AU - Moore, Amelia
AU - Green, Adrian
AU - Martinez, Lauren
AU - Stokes, Brielle
AU - Honey, Johanna
AU - Izquierdo-Barras, Alba
AU - Arbane, Gill
AU - Patel, Amita
AU - Tan, Mark Kia Ik
AU - O’Connell, Lorcan
AU - O’Hara, Geraldine
AU - MacMahon, Eithne
AU - Douthwaite, Sam
AU - Nebbia, Gaia
AU - Batra, Rahul
AU - Martinez-Nunez, Rocio
AU - Shankar-Hari, Manu
AU - Edgeworth, Jonathan D.
AU - Neil, Stuart J. D.
AU - Malim, Michael H.
AU - Doores, Katie J.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.
AB - Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.
UR - http://www.scopus.com/inward/record.url?scp=85094166805&partnerID=8YFLogxK
U2 - 10.1038/s41564-020-00813-8
DO - 10.1038/s41564-020-00813-8
M3 - Article
SN - 2058-5276
VL - 5
SP - 1598
EP - 1607
JO - Nature Microbiology
JF - Nature Microbiology
IS - 12
ER -